A 2-Part, Open Label, Adaptive, Single and/or Multiple Oral Dose, Safety, Tolerability, and Food Effect Trial of CVL-751 in Subjects With Parkinson’s Disease
tolerability, food effect trial of CVL-751 in subjects with Parkinson’s disease. Part 1 is a
placebo-controlled, single dose cohort intended for assessment of safety and tolerability. In
case of intolerable AEs, Part 2 would proceed as a multiple dose titration trial to achieve a
15 mg once daily dose while maintaining L-Dopa treatment (Part 2A). In case of a favorable
tolerability profile in Part 1, Part 2B would proceed as a single dose trial (similar to Part
1), with discontinuation of L-Dopa for 24 hours (12 hours pre-Day 1 dose and 12 hours
post-Day 1 dose).
1. Male and female subjects, ages 45 to 75 years, inclusive, at the time of signing the
informed consent form (ICF).
2. Body mass index (BMI) of 17.5 to 38.0 kg/m2 and a total body weight >50 kg (110 lbs).
3. Subjects with a diagnosis of that is consistent with the UK Parkinson’s Disease
Society Brain Bank diagnostic criteria, with bradykinesia and motor asymmetry.
4. Must be modified Hoehn & Yahr (HY) Stage I – III inclusive.
5. Must be on a stable dose of L-Dopa of at least 300 mg daily in conjunction with a
dopa-decarboxylase inhibitor (eg, L-Dopa/carbidopa or L-Dopa/benserazide) administered
at least 3 times per day but no more than 6 times per day for at least 2 weeks prior
to the Day 1 Visit. Must be willing and able to refrain from L-Dopa treatment (in Part
1 and Part 2B) as outlined in the schedule of assessments.
6. A female subject of childbearing potential (see Section 10.4, Appendix 4) who is
sexually active with a nonsterilized male partner or male subject with a pregnant or a
nonpregnant partner of childbearing potential must agree to use an acceptable or a
highly effective method of contraception (see Section 10.4, Appendix 4) from signing
of informed consent throughout the duration of the trial and for 7 days post last
7. Capable of giving signed informed consent as described in Section 10.1.3 (Appendix 1),
which includes compliance with the requirements and restrictions listed in the ICF and
in this protocol.
8. Ability, in the opinion of the investigator, to understand the nature of the trial and
comply with protocol requirements, including the prescribed dosage regimens, scheduled
visits, laboratory tests, and other trial procedures.
9. Capable of consuming the standard high-fat meal.
1. Any significant Axis I psychiatric disease as defined by the Diagnostic and
Statistical Manual of Mental Disorders, 5th edition (American Psychiatric
2. In the opinion of the investigator (or caregiver, as applicable), has signs/symptoms
suggestive of clinically significant cognitive impairment that would interfere with
the ability to comply with trial procedures.
3. Subjects with a Montreal Cognitive Assessment score <26. 4. History or clinical features consistent with an atypical parkinsonian syndrome (eg, ataxia, dystonia, clinically significant orthostatic hypotension). 5. Has a history of psychotic symptoms requiring treatment with an antipsychotic medication within the 12 months prior to signing ICF. 6. Subjects with epilepsy, or history of epilepsy, or conditions that lower seizure threshold, seizures of any etiology (including substance or drug withdrawal), or who have increased risk of seizures as evidenced by history of electroencephalogram with epileptiform activity. Subjects with a history of febrile seizures only are allowed. Subjects with a history of head trauma with loss of consciousness requiring overnight hospitalization will be excluded as well. 7. Subjects with a current history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, hematological, immunological, or neurological disease that, in the opinion of the investigator or medical monitor, could compromise either subject safety or the results of the trial. Medical conditions that are minor or well-controlled may be considered acceptable if the condition does not expose the subject to an undue risk of a significant AE or interfere with the assessments of safety or efficacy during the course of the trial. The medical monitor should be contacted in any instance where the investigator is uncertain regarding the stability of a subject's medical conditions(s) and the potential impact of the condition(s) on trial participation. 8. History of substance or alcohol-use disorder (excluding nicotine; Diagnostic and Statistical Manual of Mental Disorders, 5th edition criteria) within 2 years prior to signing the ICF. 9. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males [1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor] within 6 months prior to signing ICF. 10. If a current smoker, is unable to comply with the following guidelines: agrees not to smoke on the mornings of trial dosing days and for the entire trial dosing day until completion of all trial assessments for that day. 11. Subjects who answer "Yes" on the Columbia-Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation Item 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) and whose most recent episode meeting criteria for this C-SSRS Item 4 occurred within the last 6 months, OR Subjects who answer "Yes" on the C-SSRS Suicidal Ideation Item 5 (Active Suicidal Ideation with Specific Plan and Intent) and whose most recent episode meeting criteria for this C-SSRS Item 5 occurred within the last 6 months OR Subjects who answer "Yes" on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) and whose most recent episode meeting criteria for any of these 5 C-SSRS Suicidal Behavior Items occurred within the last 2 years, OR Subjects who, in the opinion of the investigator, present a serious risk of suicide. 12. Subjects who have attempted suicide in the past. 13. Human immunodeficiency virus seropositive status or acquired immunodeficiency syndrome, acute or chronic hepatitis B or C, with HbsAg, or hepatitis C virus antibodies at screening. 14. Subjects with a positive drug screen for illicit drugs are excluded and may not be retested or rescreened. Subjects with a positive urine drug screen resulting from use of marijuana (any cannabinoids), prescription medications, over-the-counter medications, or products that, in the investigator's documented opinion, do not signal a clinical condition that would impact the safety of the subject or interpretation of the trial results may continue evaluation for the trial following consultation and approval by the medical monitor. 15. Subjects with a 12-lead electrocardiogram (ECG) demonstrating the following: • QT interval corrected for heart rate using Fridericia's formula (QTcF) >450 msec.
16. Subjects with any of the following abnormalities in clinical laboratory tests at the
Screening Visit, as assessed by the central laboratory and confirmed by a single
repeat measurement, if deemed necessary:
– Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2 × upper
limit of normal (ULN)
– Total bilirubin ≥1.5 × ULN. Subjects with a history of Gilbert’s syndrome may be
eligible provided the direct bilirubin is